Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Argen X SE (ARGX) EUR0.10

Sell:€220.00 Buy:€230.00 Change: €7.00 (3.14%)
Market closed |  Prices as at close on 26 November 2020 | Switch to live prices |
Sell:€220.00
Buy:€230.00
Change: €7.00 (3.14%)
Market closed |  Prices as at close on 26 November 2020 | Switch to live prices |
Sell:€220.00
Buy:€230.00
Change: €7.00 (3.14%)
Market closed |  Prices as at close on 26 November 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Contact details

Address:
Willemstraat 5
BREDA
4811 AH
Netherlands
Telephone:
+31 (76) 3030488

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ARGX
ISIN:
NL0010832176
Market cap:
€10.46 billion
Shares in issue:
47.11 million
Sector:
Biotechnology
Exchange:
Euronext Brussels
Country:
Belgium
Currency:
Euro
Indices:
BEL 20

Key personnel

  • Tim Van Hauwermeiren
    Chief Executive Officer, Co-Founder, Executive Director
  • Eric Castaldi
    Chief Financial Officer
  • Keith Woods
    Chief Operating Officer
  • Hans de Haard
    Chief Scientific Officer
  • Arjen Lemmen
    Vice President - Corporate Development and Strategy
  • Dirk Beeusaert
    General Counsel
  • Wim Parys
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.